Table 1 Clinico-pathologic annotation of PDX models. 5-FU: 5-fluorouracil; Ox: oxaliplatin; Ir: irinotecan; Cet: cetuximab; Bev: bevacizumab.

From: A multi-modal data resource for investigating topographic heterogeneity in patient-derived xenograft tumors

Model

PDX-L1 (footnote 1)

PDX-L2

PDX-R1*

PDX-R2 (footnote 1)

Primary tumor location

Left colon

Left colon

Right colon

Right colon

Biopsy site

Vaginal wall

Ovary

Liver

Periumbilical soft tissue

Patient sex

Female

Female

Male

Female

Age at diagnosis

64

61

28

62

Race/ethnicity

White/non-hispanic

White/non-hispanic

White/non-hispanic

White/non-hispanic

Histology†

Mucinous Adenocarcinoma, pools of mucin, segmental and dirty necrosis

Adenocarcinoma, not otherwise specified

Adenocarcinoma, extensive angiolymphatic invasion

Adenocarcinoma, not otherwise specified

Stage at diagnosis

T3N1M0

T3N2M1

T4N2M1

T3N0M1

Tumor grade

Intermediate

Low

High

Unknown

Genetics‡

BRAF (V600E)

TP53 (c.96 + 1 G > T)

BRAF (V600E), TP53 (I195N), PIK3CA (G1049S)

BRAF (V600E), TP53 (R175H)

Lines of chemo prior to biopsy

3

 1

3

2

Prior chemotherapy agents

5-FU, Ox, Ir, Cetux, Bev

5-FU, Ox

5-FU, Ox, Ir, Cetux, Bev

5-FU, Ox, Ir, Bev

PDX passage #

6

1

2

5

  1. *Genetic and proteomic profiling also performed on patient tumor biopsy sample; response to targeted therapies was recapitulated in the xenograft model15.
  2. †Histology of patient tumor was conserved in the corresponding xenograft (Fig. 2a).
  3. ‡Mutations common to patient tumor and xenograft model; all cancers were microsatellite stable.
Back to article page